DelveInsight’s, “Gastric Cancer Pipeline Insight 2023” report provides comprehensive insights about 180+ Gastric Cancer companies and 200+ pipeline drugs in the Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gastric Cancer Pipeline Report
- DelveInsight’s Gastric Cancer pipeline report depicts a robust space with 180+ companies working to develop 200+ pipeline Gastric Cancer.
- The leading Gastric Cancer companies working in the market include Linton Pharm Co.Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, TaihoOncology Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co. Ltd, Shanghai MiracogenInc., RemeGen Co Ltd., Idience Co. Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co.Ltd., Macro Genics, Sichuan Baili Pharmaceutical Co. Ltd., LianBio LLC, Janssen Pharmaceutical, and others.
- Promising Gastric Cancer Pipeline Therapies in the various stages of development include S-1/Cisplatin, FLX475, Pembrolizumab, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Volitinib, Docetaxel, and others.
- December 2023: Hanmi Pharmaceutical Company Limited announced a study of Phase 2 clinical trials for Pembrolizumab and FLX475. This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer. This study is designed to assess the potential anti-tumor activity when administered at the 100mg QD of FLX475 with pembrolizumab and will be conducted (2) cohorts.
- December 2023: Ono Pharmaceuticals Co. Ltd, announced a study of Phase 3 clinical trials for Nivolumab, Oxaliplatin and Capecitabine. The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.
- December 2023: RemeGen Co. Ltd announced a study of Phase 3 clinical trials for RC48-ADC and Apatinib Mesylate Tablets. This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare RC48-ADC to physician choice standard treatment in participants with human epidermal growth factor receptor 2 (HER2)-overexpression locally advanced or metastatic gastric cancer.
- December 2023: Merck Sharp & Dohme LLC announced a study of Phase 2 clinical trials for Pembrolizumab, Oxaliplatin, and Cisplatin. The purpose of this study is to estimate objective response rates (ORRs) of pembrolizumab + oxaliplatin + TS-1 and pembrolizumab + cisplatin + TS-1, as first-line treatment for gastric cancer in programmed death-ligand 1 (PD-L1) positive, human epidermal growth factor receptor 2 (HER2/neu)-negative participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- December 2023: Sanofi announced a study of Phase 3 clinical trials for Docetaxel (XRP6976) and Oxaliplatin (SR96669). Participants in the neoadjuvant chemotherapy arm were treated for 3 cycles (1 cycle is 21 days) before surgery and treated for a year with S-1. Participants in the adjuvant chemotherapy arm underwent surgery and were treated for a year with S-1.
Request a sample and discover the recent advances in Gastric Cancer Drugs @ Gastric Cancer Pipeline Outlook Report
In the Gastric Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Gastric Cancer clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the Gastric Cancer pipeline products under development.
Gastric Cancer Overview
Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. About 95% of the time, stomach cancer starts in the stomach lining and progresses slowly. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer. Stomach cancer forms when there’s a genetic mutation (change) in the DNA of stomach cells. DNA is the code that tells cells when to grow and when to die. Because of the mutation, the cells grow rapidly and eventually form a tumor instead of dying. The cancer cells overtake healthy cells and may spread to other parts of the body (metastasize).
Find out more about Gastric Cancer Analysis @ Gastric Cancer Drugs
Gastric Cancer Emerging Drugs
- Catumaxomab: Linton Pharm Co. Ltd.
- HLX10: Shanghai Henlius Biotech
- FLX475: RAPT Therapeutics
- Savolitinib: AstraZeneca/HUTCHMED
- ASP 2138: Astellas Pharma
- Minnelide : Minneamrita Therapeutics LLC
Gastric Cancer Therapeutics Assessment
There are approx. 180+ Gastric Cancer companies which are developing the therapies for Gastric Cancer. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd. The Gastric Cancer pipeline report proffers an integral view of the emerging Gastric Cancer segmented by stage, product type, molecule type, and route of administration.
Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Dive deep into rich insights for new Gastric Cancer, visit @ Gastric Cancer Treatment Landscape
Gastric Cancer Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Scope of the Gastric Cancer Pipeline Report
- Coverage- Global
- Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Gastric Cancer Companies- Linton Pharm Co.Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, TaihoOncology Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co. Ltd, Shanghai MiracogenInc., RemeGen Co Ltd., Idience Co. Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co.Ltd., Macro Genics, Sichuan Baili Pharmaceutical Co. Ltd., LianBio LLC, Janssen Pharmaceutical, and others.
- Gastric Cancer Pipeline Therapies- S-1/Cisplatin, FLX475, Pembrolizumab, Tegafur-gimeracil-oteracil potassium, Oxaliplatin, Volitinib, Docetaxel, and others.
For further information on the Gastric Cancer Pipeline Therapeutics, reach out @ Gastric Cancer Therapeutics Segmentation
Table of Content
- Introduction
- Executive Summary
- Gastric Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Comparative Analysis
- Catumaxomab: Neovii Biotech
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- FLX475: RAPT Therapeutics
- Early Stage Products (Phase I)
- Comparative Analysis
- ASP 2138: Astellas Pharma
- Inactive Products
- Gastric Cancer Key Companies
- Gastric Cancer Key Products
- Gastric Cancer – Unmet Needs
- Gastric Cancer – Market Drivers and Barriers
- Gastric Cancer – Future Perspectives and Conclusion
- Gastric Cancer Analyst Views
- Gastric Cancer Key Companies
- Appendix
Find out more about Gastric Cancer Therapeutics Assessment @ Gastric Cancer Preclinical and Discovery Stage Products
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market